

## Intensive glucose control offers lasting reduction in risk of ESKD

March 29 2016



(HealthDay)—For patients with type 2 diabetes, intensive glucose



control has long-term benefits for preventing end-stage kidney disease (ESKD), according to a study published online March 22 in *Diabetes Care*.

Muh Geot Wong, M.D., Ph.D., from the University of Sydney, and colleagues examined the long-term effects of intensive glucose control on the risk of ESKD and other outcomes in survivors of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Released Controlled Evaluation (ADVANCE) trial. A total of 8,494 ADVANCE participants, who had previously been randomized to intensive or standard glucose control, participated in a post-trial follow-up.

The researchers found that by the first post-trial visit, in-trial hemoglobin A1c differences disappeared. After 9.9 years of overall follow-up, the in-trial reduction in the risk of ESKD (seven versus 20 events; hazard ratio, 0.35; P = 0.02) persisted (29 versus 53 events; hazard ratio, 0.54; P blood pressure (P = 0.01). The glucose lowering effects on death, cardiovascular death, or major cardiovascular event risks did not vary according to levels of kidney function (P > 0.26).

"Intensive glucose control was associated with a long-term reduction in ESKD, without evidence of any increased risk of cardiovascular events or death," the authors write. "These benefits were greater with preserved kidney function and with well-controlled blood pressure."

Several authors disclosed financial ties to the pharmaceutical industry; the ADVANCE trial and ADVANCE-ON follow-up study were partially funded by grants from Servier.

**More information:** Abstract

Full Text (subscription or payment may be required)



Copyright © 2016 HealthDay. All rights reserved.

Citation: Intensive glucose control offers lasting reduction in risk of ESKD (2016, March 29) retrieved 5 July 2024 from <a href="https://medicalxpress.com/news/2016-03-intensive-glucose-reduction-eskd.html">https://medicalxpress.com/news/2016-03-intensive-glucose-reduction-eskd.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.